NSC348884
Based on 4 publication(s) in Google Scholar
NSC348884 is a nucleophosmin (NPM) inhibitor, it disrupts oligomer formation and induces apoptosis, inhibits cell proliferation with IC50s of 1.7-4.0 μM in distinct cancer cell lines. NSC348884 can be used for the research of cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.40%
- CAS No.: 81624-55-7
- 화학식: C38H40N10
- 분자량:636.79
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Blood Cancer Compound Library
HY-L079
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) NSC348884
More
Customer Validation & Images
-
WB
-
IF
-
Cell Proliferation/Viability Assay
-
RT-PCR
Biological Activity
IC50: 4 μM (LNCaP cells), 1.7 μM (Granta cells)[1]
NSC348884 (0-6 μM; 24 h) binds with NPM and disrupts NPM oligomer formation[1]. NSC348884 (0.01-100 μM; 4 d) shows cytotoxicity to cancer cells[1]. NSC348884 (1 μM; 4 d) shows cytotoxicity to mantle cell lymphoma with 0.1 nM doxorubicin[1]. NSC348884 (1-5 μM; 24 h) induces cell apoptosis[1]. NSC348884 (0-5 μM; 0-24 h) upregulates the concentration of p53[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LNCaP and Granta cell lines
-
Concentration:0.01-100 μM
-
Incubation Time:4 days
-
Result:Inhibited LNCaP cells and Granta cell lines with IC50s of 4 and 1.7 μM, respectively.
-
Cell Line:LNCaP cell line
-
Concentration:1-5 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in LNCaP cell line.
-
Cell Line:LNCaP cell line
-
Concentration:0-5 μM
-
Incubation Time:0-24 h
-
Result:Dose-dependently increased both p53 protein level and phosphorylation on Ser15, and increased the concentration of p21.
-
Cell Line:SKOV3, ES2 and MOSEC/Luc cell lines
-
Concentration:0, 2.5 and 5 μM
-
Incubation Time:48 h
-
Result:Increased PD-L1 expression in ovarian cancer cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6J mice with MOSEC/Luc cells injection[2]
-
Dosage:50 μg
-
Administration:Intraperitoneal injection; 50 μg once
-
Result:Reduced tumorigenesis, but not completely inhibited.
Chemical Information
-
CAS No. 81624-55-7
-
Appearance Solid
-
분자량 636.79
-
화학식 C38H40N10
-
Color Light yellow to yellow
-
SMILES
CC1=CC=C2N=C(CN(CC3=NC4=CC=C(C)C=C4N3)CCN(CC5=NC6=CC=C(C)C=C6N5)CC7=NC8=CC=C(C)C=C8N7)NC2=C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Hematol Oncol
NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression. [Abstract]2024 Oct 14;17(1):97. PMID: 39402629 -
Front Microbiol
Nucleolar Phosphoprotein NPM1 Interacts With Porcine Circovirus Type 3 Cap Protein and Facilitates Viral Replication. [Abstract]2021 May 25:12:679341. PMID: 34113334
NSC348884 purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 May 25:12:679341. [Abstract]
NPM1 inhibitor NSC348884 (0.1, 1 μM) and DMSO-treated cells were infected with PCV3 for 48, 72, and 96 h. Western blot was used to examine the expression levels of Cap, NPM1, and β-actin
NSC348884 purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 May 25:12:679341. [Abstract]
NPM1 expression in NSC348884 (1 μM)- and DMSO-treated cells analyzed by immunofluorescence.
NSC348884 purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 May 25:12:679341. [Abstract]
Viability of PK15 cells treated with NSC348884 (0.1, 1 μM) and DMSO analyzed using a CCK-8 assay.
NSC348884 purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 May 25:12:679341. [Abstract]
qPCR was exploited to determine the expression level of Cap gene treated with NSC348884.
-
-
Eur Rev Med Pharmacol Sci
The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells. [Abstract]2023 Oct;27(19):9145-9151. PMID: 37843328
용액&용해도
DMSO : ≥ 34 mg/mL (53.39 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (3.93 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.93 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5704 mL | 7.8519 mL | 15.7038 mL | 39.2594 mL |
| 5 mM | 0.3141 mL | 1.5704 mL | 3.1408 mL | 7.8519 mL | |
| 10 mM | 0.1570 mL | 0.7852 mL | 1.5704 mL | 3.9259 mL | |
| 15 mM | 0.1047 mL | 0.5235 mL | 1.0469 mL | 2.6173 mL | |
| 20 mM | 0.0785 mL | 0.3926 mL | 0.7852 mL | 1.9630 mL | |
| 25 mM | 0.0628 mL | 0.3141 mL | 0.6282 mL | 1.5704 mL | |
| 30 mM | 0.0523 mL | 0.2617 mL | 0.5235 mL | 1.3086 mL | |
| 40 mM | 0.0393 mL | 0.1963 mL | 0.3926 mL | 0.9815 mL | |
| 50 mM | 0.0314 mL | 0.1570 mL | 0.3141 mL | 0.7852 mL |
NSC348884 Related Classifications
HY-13915 Related Classifications
Powered by Bioz